Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2296 to 2310 of 8314 results

  1. Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]

    Awaiting development Reference number: GID-TA11792 Expected publication date: TBC

  2. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [TSID12036]

    Awaiting development Reference number: GID-TA11596 Expected publication date: TBC

  3. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

    Topic prioritisation

  4. Cytokine adsorption technologies for treating respiratory failure in people with COVID-19

    Topic prioritisation

  5. Archimedes for biopsy of suspected lung cancer

    Topic prioritisation

  6. Actim Pancreatitis for diagnosing acute pancreatitis

    Topic prioritisation

  7. PCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms

    Topic prioritisation

  8. Spartan RX point-of-care CYP2C19 test

    Topic prioritisation

  9. Healthy.io test for home testing of urine albumin to creatinine ratio

    Topic prioritisation

  10. FebriDx for C-reactive protein and myxovirus resistance protein A testing

    Topic prioritisation

  11. Helge for detecting haemolysis

    Topic prioritisation

  12. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds

    Topic prioritisation

  13. MT547 QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

    Topic prioritisation

  14. Suspected cancer update

    In development Reference number: GID-QS10176 Expected publication date: TBC

  15. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development Reference number: GID-TA11137 Expected publication date: TBC